Riociguat is used for treating chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) to improve exercise capacity and WHO functional class, and delay clinical worsening. It was first introduced by Bayer Healthcare Pharmaceuticals Inc in its drug Adempas on Oct 8, 2013. 2 different companies have introduced drugs containing Riociguat.

Riociguat Patents

Given below is the list of patents protecting Riociguat, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Adempas	US10662188	Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate	Feb 18, 2034	Bayer Hlthcare
Adempas	US11203593	Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate	Feb 18, 2034	Bayer Hlthcare
Adempas	US7173037	Carbamate-substituted pyrazolopyridines	Dec 04, 2026	Bayer Hlthcare
Adempas	US6743798	Substituted pyrazole derivatives condensed with six-membered heterocyclic rings	Jul 16, 2019 (Expired)	Bayer Hlthcare

Add above patents to watchlist

Riociguat's Family Patents

Full family tree

Riociguat Generic API Manufacturers

Several generic applications have been filed for Riociguat.

Given below is the list of companies who have filed for Riociguat generic, along with the locations of their manufacturing plants worldwide.